select trial semaglutide cardiovascular outcomes non-diabetic 2023 #VisualAbstract: and in Obesity without Diabetes select trial semaglutide cardiovascular outcomes

As your dose gradually increases in line with prescribing guidelines, semaglutide continues to influence appetite

Eligibility for semaglutide GLP-1 is assessed through consultation with healthcare providers who specialize in weight management, such as those at Vive Ageless Weight Loss Center

EnginOKzlrmak KarataASTapnarBTapnarF

This leads to a feeling of fullness that lasts longer after eating, which can help reduce your overall food intake and support weight loss efforts

Weight loss was accompanied by improvements in cardiometabolic parameters, including a decrease in systolic blood pressure (-9.9 mmHg) and waist circumference (-17.5 cm) (placebo-adjusted: 6.7 mmHg and 13.5 cm, respectively)

This may include medical records, statements from healthcare providers, and any other documentation that highlights the necessity of the treatment